Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/193134
Full metadata record
DC FieldValueLanguage
dc.contributor.authorClèries Soler, Ramon-
dc.contributor.authorAmeijide, Alberto-
dc.contributor.authorBuxó, Maria-
dc.contributor.authorVilardell, Mireia-
dc.contributor.authorMartínez, José Miguel-
dc.contributor.authorFont, Rebeca-
dc.contributor.authorMarcos Gragera, Rafael-
dc.contributor.authorPuigdemont, Montse-
dc.contributor.authorViñas, Gemma-
dc.contributor.authorCarulla, Marià-
dc.contributor.authorEspinàs Piñol, Josep Alfons-
dc.contributor.authorGalceran, Jaume-
dc.contributor.authorIzquierdo, Ángel-
dc.contributor.authorBorràs Andrés, Josep Maria-
dc.date.accessioned2023-02-06T09:37:15Z-
dc.date.available2023-02-06T09:37:15Z-
dc.date.issued2022-12-27-
dc.identifier.issn1660-4601-
dc.identifier.urihttp://hdl.handle.net/2445/193134-
dc.description.abstractMortality from cardiovascular disease (CVD), second tumours, and other causes is of clinical interest in the long-term follow-up of breast cancer (BC) patients. Using a cohort of BC patients (N = 6758) from the cancer registries of Girona and Tarragona (north-eastern Spain), we studied the 10-year probabilities of death due to BC, other cancers, and CVD according to stage at diagnosis and hormone receptor (HR) status. Among the non-BC causes of death (N = 720), CVD (N = 218) surpassed other cancers (N = 196). The BC cohort presented a significantly higher risk of death due to endometrial and ovarian cancers than the general population. In Stage I, HR- patients showed a 1.72-fold higher probability of all-cause death and a 6.11-fold higher probability of breast cancer death than HR+ patients. In Stages II-III, the probability of CVD death (range 3.11% to 3.86%) surpassed that of other cancers (range 0.54% to 3.11%). In Stage IV patients, the probability of death from any cancer drove the mortality risk. Promoting screening and preventive measures in BC patients are warranted, since long-term control should encompass early detection of second neoplasms, ruling out the possibility of late recurrence. In patients diagnosed in Stages II-III at an older age, surveillance for preventing late cardiotoxicity is crucial.-
dc.format.extent17 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherMDPI AG-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/ijerph20010405-
dc.relation.ispartofInternational Journal of Environmental Research and Public Health, 2022, vol. 20, num. 1, p. 405-
dc.relation.urihttps://doi.org/10.3390/ijerph20010405-
dc.rightscc by (c) Clèries Soler, Ramon et al., 2022-
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.sourceArticles publicats en revistes (Ciències Clíniques)-
dc.subject.classificationCàncer de mama-
dc.subject.classificationMalalties cardiovasculars-
dc.subject.classificationMortalitat-
dc.subject.otherBreast cancer-
dc.subject.otherCardiovascular diseases-
dc.subject.otherMortality-
dc.titleTen-Year Probabilities of Death Due to Cancer and Cardiovascular Disease among Breast Cancer Patients Diagnosed in North-Eastern Spain-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.date.updated2023-02-02T10:27:39Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
Appears in Collections:Articles publicats en revistes (Ciències Clíniques)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
ijerph-20-00405.pdf4.58 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons